- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '84153'
    - '84154'
    loinc:
    - 33747-0
    - 10886-0
  conditions:
    any_of:
    - dx_in_value_set: vs_prostate_screening_eligible_2025_09
    - dx_in_value_set: vs_prostate_cancer_risk_2025_09
    all_of:
    - age_gte: 50
    - age_lte: 75
    - has_flag: life_expectancy_gt_10_years
    none_of:
    - has_flag: life_expectancy_less_10_years
  logic:
    outcome: PA_REQUIRED
    note: PSA screening for prostate cancer in average-risk men aged 50-75
  precedence: 80
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_6376281c3547
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '55700'
    - '55706'
    loinc:
    - 33747-0
  conditions:
    any_of:
    - dx_in_value_set: vs_elevated_psa_2025_09
    - dx_in_value_set: vs_abnormal_dre_2025_09
    all_of:
    - age_gte: 40
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: active_prostatitis
    - has_flag: bleeding_disorder
  logic:
    outcome: PA_REQUIRED
    note: Prostate biopsy for elevated PSA or abnormal digital rectal exam
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_48f5c3577b54
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '55706'
    - '76376'
    - '76377'
    loinc:
    - 33747-0
  conditions:
    any_of:
    - dx_in_value_set: vs_prior_negative_biopsy_2025_09
    - dx_in_value_set: vs_active_surveillance_2025_09
    all_of:
    - age_gte: 40
    - has_flag: specialist_evaluation
    - has_flag: mri_compatible
    none_of:
    - has_flag: claustrophobia
    - has_flag: metallic_implants
  logic:
    outcome: PA_REQUIRED
    note: MRI-guided prostate biopsy for prior negative biopsy or active surveillance
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_7b17620deb8c
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '81479'
    - '81599'
  conditions:
    any_of:
    - dx_in_value_set: vs_prostate_cancer_low_risk_2025_09
    - dx_in_value_set: vs_prostate_cancer_intermediate_risk_2025_09
    all_of:
    - age_gte: 40
    - has_flag: confirmed_prostate_cancer
    - has_flag: specialist_evaluation
    none_of: []
  logic:
    outcome: PA_REQUIRED
    note: Genomic testing for prostate cancer risk stratification
  precedence: 85
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_3ebc027b1ccb
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '84153'
    - '55700'
    - '76872'
    loinc:
    - 33747-0
  conditions:
    any_of:
    - dx_in_value_set: vs_prostate_cancer_very_low_risk_2025_09
    - dx_in_value_set: vs_prostate_cancer_low_risk_2025_09
    all_of:
    - age_gte: 40
    - has_flag: active_surveillance_candidate
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: patient_anxiety
    - has_flag: non_compliance
  logic:
    outcome: PA_REQUIRED
    note: Active surveillance protocol for very low and low-risk prostate cancer
  precedence: 85
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_82701827eec6
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '78815'
    - '78816'
    hcpcs:
    - A9588
    loinc:
    - 33747-0
  conditions:
    any_of:
    - dx_in_value_set: vs_prostate_cancer_high_risk_2025_09
    - dx_in_value_set: vs_prostate_cancer_recurrent_2025_09
    all_of:
    - age_gte: 40
    - has_flag: specialist_evaluation
    - has_flag: staging_workup_indicated
    none_of: []
  logic:
    outcome: PA_REQUIRED
    note: PSMA PET imaging for high-risk or recurrent prostate cancer
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_urology_prostate_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_f22ce470b60f
